Head and Neck Cancer clinical trials in New Jersey
35 active Head and Neck Cancer trials with a site in New Jersey. Describe your situation to see which ones you may be eligible for.
- A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
- A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
- A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
- A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
- A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- XTX301 in Patients With Advanced Solid Tumors
- A Study of CRD3874-SI in People With Solid Tumors
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
- A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.